

# Intention to use long-acting PrEP among MSM in Europe – results from the PROTECT survey from Spain, Italy, Germany, France and the United Kingdom.



Maastricht University

Kai J. Jonas<sup>1</sup>, Johann Kolstee<sup>1</sup>, Haoyi Wang<sup>1</sup>, Alejandro Adriaque Lozano<sup>1</sup>, Julio C. Croce<sup>1</sup>, Melanie Schroeder<sup>2</sup>, Ama Appiah<sup>2</sup>, Carolyn Brown<sup>3</sup>, Ana Milinkovic<sup>2,4</sup>, Jenny Scherzer<sup>5</sup>, Hanne M.L. Zimmermann<sup>1</sup>

<sup>1</sup>Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands; <sup>2</sup>ViiV Healthcare Ltd, Brentford, UK; <sup>3</sup>ViiV Healthcare Ltd, Durham, NC USA; <sup>4</sup>Chelsea and Westminster Hospital, London, UK; <sup>5</sup>ViiV Healthcare Ltd, Munich, Germany

## LONG ACTING PREP AS A NEW MODALITY


Recently, long-acting injectable PrEP for HIV (LA-PrEP), Cabotegravir/Apretude®, has been approved for use in Europe. Understanding who shows interest and intent to use LA-PrEP is pivotal to help ending the HIV epidemic. Even in decreasing epidemics, such as in Europe, all available modalities should be available as HIV prevention options. Thus, it is paramount to investigate who is most interest and can benefit from this modality.

The Pre-exposure pRophylaxis mOdalities for HIV prevention in the European CommuniTies (PROTECT) Survey was a cross-sectional online survey that collected data in 20 European countries.


This is the analysis of data collected in the UK, Germany, Spain, Italy and France from October 2023 to March 2024 among MSM older than 18 years. Data from MSM participants residing in the 5 countries were analysed to produce descriptive data and to undertake multivariate regression analyses to determine factors associated with intention to use LA-PrEP. A total of 9140 surveys were completed by MSM and included in this analysis.

## SAMPLING AND SAMPLING CHARACTERISTICS

- 9140 MSM participated in 5 countries (Germany, UK, France, Spain and Italy)
- Onling sampling occurred between October 2023 and March 2024




## HIV TESTING, SEX PARTNERS, PREP USE, CHEMSEX




## INTEREST AND INTENTION TO USE LA-PREP


### INTEREST IN LA-PREP



### INTENTION TO USE LA-PREP



## MULTIVARIABLE DETERMINANT ANALYSIS



**KEY MESSAGE 1: MSM SHOW SUBSTANTIAL INTEREST IN LONG-ACTING PREP AND HAVE ROBUST INTENTIONS TO USE IT. INTEREST AND INTENTION ARE HIGHER AMONG CURRENT PREP USERS**

**KEY MESSAGE 2: FOR ALL MSM, BEING A MIGRANT, HAVING MULTIPLE SEX PARTNERS, ENGAGING IN CHEMSEX, CAI, PERCEIVED HIV RISK AND WORRY, AND PAST PEP USE LEAD TO A HIGHER LIKELIHOOD FOR USE INTENTION**

**KEY MESSAGE 3: FEAR OF NEEDLES, WORRY ABOUT INJECTION PAIN, AND SIDE EFFECTS DECREASED INTENTION TO USE LIKELIHOOD**

